Advaxis, Inc. announced the completion of a previously announced merger with Ayala Pharmaceuticals, Inc. While the stock will continue to trade on OTC under the symbol ADXS, the merged company will operate under the name Ayala Pharmaceuticals. Management and Board of Directors Kenneth A Berlin, President and Chief Executive Officer of Advaxis, will be President, Chief Executive Officer and a Director of the company. The company
announced that the board of directors consists, Vered Bisker-Leib, M.D., Murray A. Goldberg, Robert Spiegel, M.D.